Rituximab Monoclonal Antibody: Mechanisms of Action Against B-Cell Lymphoma

This template was adapted from the original submission. Edits were made to enhance scientific accuracy, optimal usability and/or to meet industry-leading design standards for science communication. This template depicts the four mechanisms of action of the monoclonal antibody Rituximab against CD20-expressing B-cells. Following Rituximab binding to CD20, B-cell may undergo: direct killing mediated by Natural Killer cells, complement-mediated cytotoxicity that leads to cell lysis, antibody-dependent cell cytotoxicity mediated by perforin and granzime cytokines, and antibody-dependent phahocytosis performed by activated macrophages.

Yes, you can customize this template with a free BioRender account (no credit card required). Paid plans unlock additional export formats, higher-resolution downloads, and publication permissions.

Yes, every element is fully editable. Icons, labels, colors, arrows, shapes and layout can all be changed to match your preferences or needs using BioRender's drag-and-drop editor. You can add or remove elements to fully customize your use case.

Yes, BioRender icons and templates meet journal, grant, and copyright standards for publication, and many researchers cite BioRender directly in their figure legends.

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Researchers and scientists use this template for publications, funding proposals, grant applications, presentations, posters, and more.